Oklahoma 2023 2023 Regular Session

Oklahoma House Bill HB2686 Comm Sub / Bill

Filed 04/13/2023

                     
 
Req. No. 2084 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
STATE OF OKLAHOMA 
 
1st Session of the 59th Legislature (2023) 
 
COMMITTEE SUBSTITUTE 
FOR ENGROSSED 
HOUSE BILL 2686 	By: West (Rick) and Waldron of 
the House 
 
  and 
 
  Burns of the Senate 
 
 
 
 
COMMITTEE SUBSTITUTE 
 
An Act relating to substance abuse services; amending 
43A O.S. 2021, Section 3 -601, which relates to opioid 
substitution treatment programs ; requiring opioid 
substitution treatment programs to comply with 
certain federal requirements ; requiring drug abuse 
testing to be directl y observed; broadening grounds 
for certain penalties; and providing an effective 
date. 
 
 
 
 
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 
SECTION 1.     AMENDATORY     43 A O.S. 2021, Section 3-601, is 
amended to read as follows: 
Section 3-601. A.  Any Class II controlled dangerous subs tance, 
when used in this state by an opioid substitution treatment program 
for persons with a history of opioid addiction to or physiologic 
dependence on controlled dangerous substances, shall only be u sed: 
1.  In treating persons with a history of addicti on;   
 
Req. No. 2084 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
2.  In treating persons with a one -year history of opioid 
addiction to or physiolog ic dependence on control led dangerous 
substances, as defined by the Code of Federal Regulations, and 
documentation of attempting another type of treatment; or 
3.  If clinically appropriate, the program physician may waive 
the requirement of a one -year history of opioid addiction for 
consumers within six (6) months of release from a penal institution, 
for consumers with a pregnancy verified by the program physician, or 
for consumers having previously received treatment for opioid 
addiction and within two (2) years of discharge from that treatment 
episode. 
B.  Any conviction for a violation of the provis ions of this 
section or any rules promulgated pursuant t o the provisions of this 
section shall be a felony. 
C.  For the purposes of this section, “opioid substitution 
treatment program” means a person, private physician , or 
organization that administers or dispenses an opioid drug to a 
narcotic addict for the p urposes of detoxification or maintenance 
treatment or provides, when necessary and appropriate, comprehensive 
medical and rehabilitation services.  A private physi cian who 
administers buprenorphine wi th a waiver from the Drug Enforcement 
Administration shall not be considered an opioid substitution 
treatment program.   
 
Req. No. 2084 	Page 3  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
D.  An opioid substitution treatment program shall be certified 
by the Board of Mental Health and Subst ance Abuse Services, or the 
Commissioner of Mental Health and Substance Abuse Services upo n 
delegation by the Board, and registered with the federal Drug 
Enforcement Administration for the use of an opioid drug to treat 
narcotic addiction. 
D. E.  The Board of Mental Health and Substance Abuse Se rvices 
shall promulgate rules and standards for th e certification of all 
programs, private facilities, and organization s which provide opioid 
substitution treatment directed to those physiologically dependent 
on or addicted to opioids.  These facilities an d organizations shall 
be known as “Opioid Substitution Treatment Programs”.  Only 
certified facilities may receive and assist opioid-dependent and 
addicted persons by providing Class II controlled substances in 
opioid substitution treatment and rehabilitat ion. 
E. F.  The Board of Mental Health and Substan ce Abuse Services 
shall promulgate rules and standards regulating the tr eatment and 
services provided by opioid substitution treatment p rograms.  
Failure to comply with rul es and standards promulgated by the B oard 
shall be grounds for revocation, suspensio n or nonrenewal of 
certification. 
F. G. An opioid substitution treatment program shall comply 
with all federal requirements for opioid treatment programs provided 
by 42 C.F.R., Subpart C including but not limited to t he requirement   
 
Req. No. 2084 	Page 4  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
to provide drug abuse testing services provided by 42 C.F.R., 
Section 8.12(f)(6).  Drug abuse testing shall be dire ctly observed 
by an employee or contractor of the opioid substitution treatment 
program. 
H.  Opioid substitution treatment pro grams shall notify the 
Department of Mental Health and Substance Abuse Services of plans to 
close or relocate within a minimum of thirty ( 30) days prior to 
closure or relocation. 
G. I.  Failure to comply with rules and standards promulgated by 
the Board of Mental Health and Substance Abuse Services pursuant to 
this section or failure to comply with the requirements of 42 
C.F.R., Subpart C shall be grounds for reprimand, suspension, 
revocation or nonrenewal of certification. 
SECTION 2.  This act shall become effective November 1, 2023. 
 
59-1-2084 DC 4/13/2023 11:02:43 AM